V. Moyo

发表

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

G. MacBeath, H. Hirte, I. Vergote, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

David Cunningham, G. Bodoky, D. Cunningham, 2014 .

Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Thomas, Cynthia, B. Hendriks, 2017 .

A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer.

U. Nielsen, B. Hendriks, P. LoRusso, 2012 .

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

G. MacBeath, G. Shapiro, C. Denlinger, 2021, Investigational New Drugs.

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

B. Yektashenas, M. Duh, P. Lefebvre, 2008, Annals of Hematology.

Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia

P. Srivastava, C. Runowicz, U. Hegde, 2005, Clinical Cancer Research.

Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad

Y. Bang, J. Bendell, M. Alsina, 2014 .

Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation

X. Pivot, O. Collange, Z. Huang, 2021, Journal of Controlled Release.

Iron Status in Black Persons Is Not Influenced by Haptoglobin Polymorphism

V. Gordeuk, J. Delanghe, I. Kasvosve, 2002, Clinical chemistry and laboratory medicine.

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

B. Hendriks, A. Shields, P. LoRusso, 2018, British Journal of Cancer.

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

F. Vekeman, P. Lefebvre, V. Moyo, 2009, Cancer.

Clinical and genetic heterogeneity in hereditary haemochromatosis: association between lymphocyte counts and expression of iron overload

V. Gordeuk, B. Justiça, V. Moyo, 2001, European journal of haematology.

Serum ferritin concentrations in Africans with low dietary iron

V. Gordeuk, M. Nouraie, T. Rouault, 2009, Annals of Hematology.

Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays

E. S. Garrett, R. Brodsky, V. Moyo, 2004, British journal of haematology.

Initiation of epoetin‐α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy

J. Glaspy, V. Moyo, M. Kamin, 2009, Cancer.

Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.

J. Glaspy, V. Moyo, M. Kamin, 2009, Cancer.

64 Cu-MM-302 Positron Emission Tomography Quanti ﬁ es Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

B. Hendriks, A. Shields, P. LoRusso, 2017 .

Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer

B. Hendriks, A. Shields, P. LoRusso, 2015 .

Abstract P4-15-04: Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by64Cu-MM-302 PET/CT

B. Hendriks, A. Shields, P. LoRusso, 2015 .

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Yan-Shen Shan, Paul Ross, Daniel Palmer, 2016, The Lancet.

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia.

Richard J. Jones, R. Brodsky, P. Crilley, 2002, Blood.

Effect of transferrin polymorphism on the metabolism of vitamin C in Zimbabwean adults.

V. Gordeuk, J. Delanghe, M. Langlois, 2002, The American journal of clinical nutrition.

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)

V. Grantcharova, B. Schoeberl, U. Nielsen, 2017, npj Systems Biology and Applications.

Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene.

R. Kittles, O. Onyekwere, O. Castro, 2003, Blood cells, molecules & diseases.

Effect of Ascorbic Acid Administration on Serum Concentration of Transferrin Receptors, Hlosukwazi

V. Gordeuk, T. Rouault, V. Moyo, 1998 .

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Karen Campbell, Ian Krop, Barry A Siegel, 2017, Clinical Cancer Research.

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

U. Nielsen, B. Hendriks, D. Jaffray, 2015, Molecular Cancer Therapeutics.

Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.

D. Cunningham, E. Bayever, Chung-Pin Li, 2016 .

246PA META-ANALYSIS OF BIOMARKERS IN THREE RANDOMIZED, PHASE 2 STUDIES OF MM-121, A LIGAND-BLOCKING ANTI-ERBB3 ANTIBODY, IN PATIENTS WITH OVARIAN, LUNG, AND BREAST CANCERS.

L. Sequist, G. MacBeath, J. Pearlberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

B. Hendriks, A. Shields, P. LoRusso, 2018, British Journal of Cancer.

Early growth response gene 1 (EGR1) is deleted in estrogen receptor‐negative human breast carcinoma

V. Moyo, J. Burleson, P. Benn, 2005, Cancer.

Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model

G. MacBeath, M. Curley, L. Wille, 2015, Molecular Cancer Therapeutics.

Seribantumab, an Anti-ERBB3 Antibody, Delays theOnsetofResistanceandRestoresSensitivityto LetrozoleinanEstrogenReceptor-PositiveBreast

G. MacBeath, M. Curley, L. Wille, 2015 .

Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib.

L. Sequist, D. Jackman, J. Pearlberg, 2012 .

Abstract 1072: MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model.

G. MacBeath, M. Curley, A. Brodie, 2013 .

A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.

David A. Smith, B. Hellerstedt, W. Edenfield, 2014 .

Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines

C. Benz, B. Hendriks, John W. Park, 2010 .

Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer.

U. Nielsen, M. Onsum, J. Lahdenranta, 2013 .

Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.

G. Bodoky, D. Cunningham, E. Bayever, 2015 .

Y. Bang, J. Bendell, M. Alsina, 2014 .

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Joon-Oh Park, K. Rau, C. Sternberg, 2016, The Lancet.

Rural Community in Zimbabwe Traditional Beer Consumption and the Iron Status of Spouse Pairs From a

V. Gordeuk, T. Rouault, V. Moyo, 2011 .

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

B. Hendriks, A. Shields, P. LoRusso, 2018, British Journal of Cancer.

Erratum: Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene (Blood Cells, Molecules, and Diseases (2003) 31 (299-304) DOI: 10.1016/S1079-9796(03)00164-5)

R. Kittles, O. Onyekwere, O. Castro, 2004 .